Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monopar TherapeuticsMNPR +0.82%33 EV-to-OCF is -66.71 as of Aug. 06, 2026. GuruFocus rates MNPR with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Monopar Therapeutics ranks better than 94.68% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Monopar Therapeutics's Enterprise Value is $667.93 Mil.
Monopar Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.01 Mil. Therefore, Monopar Therapeutics's EV-to-OCF for today is -66.71.
The historical rank and industry rank for Monopar Therapeutics's EV-to-OCF or its related term are showing as below:
MNPR'
s EV-to-OCF Range Over the Past 10 Years
Min: -69.45 Med: 0 Max: -66.06
Current: -66.71
During the past 10 years, the highest EV-to-OCF of Monopar Therapeutics was -66.06. The lowest was -69.45. And the median was .
MNPR's EV-to-OCF is ranked better than 94.68% of 1410
companies
in the Biotechnology industry
Industry Median: -3.41
vs MNPR: -66.71
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Monopar Therapeutics's PE Ratio (TTM) for today is calculated as:
Monopar Therapeutics's share price for today is $120.31.
Monopar Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Monopar Therapeutics EV-to-OCF Related Terms
Monopar Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Monopar Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Monopar Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's EV-to-OCF falls into.
Monopar Therapeutics's current Enterprise Value is $667.93 Mil.
Monopar Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (MNPR) has a EV-to-OCF of -66.71 as of Aug. 06, 2026. According to the industry distribution chart, Monopar Therapeutics ranks #75 out of 1410 companies in the Biotechnology industry, placing it in the top 5.3%.
Is Monopar Therapeutics' EV-to-OCF too high?
Monopar Therapeutics' current EV-to-OCF is -66.71. Based on the distribution chart, Monopar Therapeutics ranks #75 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' EV-to-OCF compare to DSGN and CLYM?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #75 out of 1410 companies for EV-to-OCF. This places Monopar Therapeutics in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Monopar Therapeutics's current EV-to-OCF is -66.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current EV-to-OCF of -66.71. The current EV-to-OCF is -66.71. Monopar Therapeutics' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current EV-to-OCF is -66.71 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
33GF Score
Get the complete analysis for MNPR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
